CN110078840A - 一种海蒿子多糖硒及其制备方法与应用 - Google Patents
一种海蒿子多糖硒及其制备方法与应用 Download PDFInfo
- Publication number
- CN110078840A CN110078840A CN201910268836.2A CN201910268836A CN110078840A CN 110078840 A CN110078840 A CN 110078840A CN 201910268836 A CN201910268836 A CN 201910268836A CN 110078840 A CN110078840 A CN 110078840A
- Authority
- CN
- China
- Prior art keywords
- sargassum
- polysaccharide
- selenium
- sargassum polysaccharide
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 155
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 155
- 150000004676 glycans Chemical class 0.000 title claims abstract description 146
- 241000195474 Sargassum Species 0.000 title claims abstract description 138
- 239000011669 selenium Substances 0.000 title claims abstract description 92
- 229910052711 selenium Inorganic materials 0.000 title claims abstract description 89
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title claims abstract description 87
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 229940091258 selenium supplement Drugs 0.000 claims abstract description 88
- 230000000694 effects Effects 0.000 claims abstract description 24
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 16
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 16
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 14
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 claims abstract description 14
- 229910001626 barium chloride Inorganic materials 0.000 claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 13
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims abstract description 11
- 238000005516 engineering process Methods 0.000 claims abstract description 11
- 229960001471 sodium selenite Drugs 0.000 claims abstract description 11
- 239000011781 sodium selenite Substances 0.000 claims abstract description 11
- 235000015921 sodium selenite Nutrition 0.000 claims abstract description 11
- 210000004369 blood Anatomy 0.000 claims abstract description 8
- 239000008280 blood Substances 0.000 claims abstract description 8
- 239000000428 dust Substances 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 238000004108 freeze drying Methods 0.000 claims abstract description 7
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 235000015872 dietary supplement Nutrition 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- 239000012141 concentrate Substances 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 23
- 239000003153 chemical reaction reagent Substances 0.000 claims description 17
- 235000019441 ethanol Nutrition 0.000 claims description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 15
- 238000005119 centrifugation Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 229960004756 ethanol Drugs 0.000 claims description 13
- -1 galactolipin Chemical compound 0.000 claims description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 11
- 239000011347 resin Substances 0.000 claims description 11
- 229920005989 resin Polymers 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 10
- 238000000502 dialysis Methods 0.000 claims description 10
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 239000008103 glucose Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 6
- 230000000996 additive effect Effects 0.000 claims description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 6
- 235000011152 sodium sulphate Nutrition 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 5
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 5
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 5
- 229910001422 barium ion Inorganic materials 0.000 claims description 5
- 238000004042 decolorization Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 230000001376 precipitating effect Effects 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 230000003068 static effect Effects 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 3
- 229910052788 barium Inorganic materials 0.000 claims description 3
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 3
- 238000005660 chlorination reaction Methods 0.000 claims description 3
- 229910017604 nitric acid Inorganic materials 0.000 claims description 3
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 claims description 2
- 238000007605 air drying Methods 0.000 claims description 2
- 230000000717 retained effect Effects 0.000 claims description 2
- 239000011435 rock Substances 0.000 claims description 2
- 239000011655 sodium selenate Substances 0.000 claims description 2
- 229960001881 sodium selenate Drugs 0.000 claims description 2
- 235000018716 sodium selenate Nutrition 0.000 claims description 2
- 240000008118 Artemisia maritima Species 0.000 claims 1
- 240000006891 Artemisia vulgaris Species 0.000 claims 1
- 241000195493 Cryptophyta Species 0.000 claims 1
- FTYIWOBJJOVZLS-UHFFFAOYSA-L S(=O)(=O)([O-])[O-].[Ba+2].[Na+] Chemical compound S(=O)(=O)([O-])[O-].[Ba+2].[Na+] FTYIWOBJJOVZLS-UHFFFAOYSA-L 0.000 claims 1
- 230000010355 oscillation Effects 0.000 claims 1
- 238000002390 rotary evaporation Methods 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 abstract description 18
- 108090000790 Enzymes Proteins 0.000 abstract description 18
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 abstract description 8
- 229960002632 acarbose Drugs 0.000 abstract description 8
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 abstract description 8
- 230000001413 cellular effect Effects 0.000 abstract description 8
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 230000002255 enzymatic effect Effects 0.000 abstract description 5
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 2
- 238000003809 water extraction Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 17
- 229940088598 enzyme Drugs 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 14
- 239000000523 sample Substances 0.000 description 10
- 150000002772 monosaccharides Chemical class 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 240000001851 Artemisia dracunculus Species 0.000 description 6
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 108010028144 alpha-Glucosidases Proteins 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229910021642 ultra pure water Inorganic materials 0.000 description 5
- 239000012498 ultrapure water Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 102000004139 alpha-Amylases Human genes 0.000 description 4
- 108090000637 alpha-Amylases Proteins 0.000 description 4
- 229940024171 alpha-amylase Drugs 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241001061264 Astragalus Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000007126 Codonopsis pilosula Species 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 206010039921 Selenium deficiency Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000006533 astragalus Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229940100688 oral solution Drugs 0.000 description 3
- 238000000197 pyrolysis Methods 0.000 description 3
- 239000011122 softwood Substances 0.000 description 3
- 210000004233 talus Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 150000003346 selenoethers Chemical class 0.000 description 2
- MCAHWIHFGHIESP-UHFFFAOYSA-N selenous acid Chemical compound O[Se](O)=O MCAHWIHFGHIESP-UHFFFAOYSA-N 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 241001661344 Artemisia desertorum Species 0.000 description 1
- 235000005492 Artemisia desertorum Nutrition 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 101500000959 Bacillus anthracis Protective antigen PA-20 Proteins 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000196222 Codium fragile Species 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241000195475 Sargassaceae Species 0.000 description 1
- 241000220690 Sargassum pallidum Species 0.000 description 1
- 102000008114 Selenoproteins Human genes 0.000 description 1
- 108010074686 Selenoproteins Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 108010052522 livetin Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000837 restrainer Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 239000011792 sodium hydrogen selenite Substances 0.000 description 1
- 235000013271 sodium hydrogen selenite Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- OHYAUPVXSYITQV-UHFFFAOYSA-M sodium;hydrogen selenite Chemical compound [Na+].O[Se]([O-])=O OHYAUPVXSYITQV-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Materials Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Sustainable Development (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种海蒿子多糖硒及其制备方法与应用。该制备方法主要包括原料预处理、热水提取、脱色、脱蛋白、冷冻干燥和硒化反应;其中,硒化反应是将海蒿子多糖与稀硝酸混合,室温下搅拌,然后分别加入亚硒酸钠和氯化钡,加热至60~80℃,搅拌混匀,于100~500W微波功率下,反应3~5min,得海蒿子多糖硒溶液,冷却到室温后,置于透析袋进行透析,冷冻干燥得海蒿子多糖硒。本发明制备方法简单,反应条件温和,无污染,硒化程度高,具有显著的α‑葡萄糖苷酶抑制活性,其活性优于阿卡波糖,且能显著提高细胞抗氧化酶活性,降低丙二醛的含量,可开发一种具有抗氧化和降血糖功效的膳食补充剂,应用于食品或医药领域。
Description
技术领域
本发明涉及功能性食品和医药领域,具体涉及一种海蒿子多糖硒及其制备方法与在制备抗氧化和降血糖健康食品和药品中的应用。
背景技术
海蒿子(Sargassum pallidum)习称“大叶海藻”,属于褐藻门马尾藻科,广泛分布于暖温带水域,海蒿子植物形态呈皱缩卷曲,长度范围为30~60cm;圆柱形主干,两侧发出主枝,主枝叶腋处生出侧枝;单叶互生,初生叶和次生叶呈披针形或线形等,固着器呈盘状,黑褐色气囊直径为2~5mm,球形或倒卵形。海蒿子水浸后膨胀,具有粘滑、柔软、味咸等特点。海蒿子在我国的渤海、黄海、东海等区有广泛的分布,生长于低潮线下海水激荡处的岩石上,暗褐色,是典型的海洋褐藻,性味苦咸、寒,入脾、肾、肺。功能主治利水、泄热、疼痛核肿、慢性气管炎等,具有很高的药用价值。对褐、红、蓝、绿海藻的多糖研究表明褐藻多糖具有比较显著的生物活性,开发前景十分广阔。海蒿子富有多种营养成分并含有大量的褐藻多糖,主要由褐藻胶、褐藻糖胶和褐藻淀粉组成。
现有技术中对于海蒿子多糖有一定的研究基础,例如:李湘师等(食品工业科技,2015,36:101-106;海蒿子多糖的提取分离机及其生物活性,硕士论文,2015)研究了海蒿子多糖的不同提取方法、理化性质、分离纯化和生物活性,当海蒿子粗多糖浓度为2mg/mL时,对α-淀粉酶、α-D-葡萄糖苷酶、蔗糖酶、麦芽糖酶的抑制率依次为85.02%、53.25%、42.96%和49.67%;当500μg/mL浓度时,对HepG2和SiHa细胞的抑制率分别为28.92%,和27.29%。方飞等(安徽农业科学,2011,39(16):9590-9591)报道了海蒿子多糖具有良好的体外羟基自由基(.OH)、超氧阴离子自由基(O2-·)的清除作用及对卵黄蛋白(LPO)的抑制作用。赵宇(海蒿子多糖的提取、分离纯化及结构研究,硕士论文,2004)报道了海蒿子多糖由木糖、岩藻糖、半乳糖、果糖、甘露糖和葡萄糖组成,具有良好的抗白血病及肺癌活性。李俊卿等(天然产物研究与开发,2005,17:564-567)经过热水抽提、乙醇沉淀和DEAE-SephadexA-25柱层析分离,得到两种海蒿子多糖组分DEI和DEII,单糖均为木糖、岩藻糖、半乳糖、果糖、甘露糖、葡萄糖。其中岩藻糖含量最高,对P388肿瘤具有抑制活性。因此,现有技术表明海蒿子多糖具有良好的生物活性,具有开发应用价值,但是现有技术尚未发现海蒿子多糖具有细胞抗氧化酶活性和α-葡萄糖甘酶的抑制活性。
目前现有技术表明硒化改性能够显著提高多糖的生物活性。中国发明专利申请CN200910161061.5公开了一种微波合成硒化多糖的方法,该方法以亚硒酸氢钠和氯化亚砜合成硒化试剂,以N,N-二甲基甲酰胺为溶剂,沙蒿多糖或蕨麻为原料,微波合成硒化多糖。中国发明专利CN201611189833.2公开了一种有机法制备硒化黄芪多糖的方法,该方法将黄芪多糖加入到脱水吡啶中,然后滴入氯化亚硒酰和丁二酸,搅拌后加入硝酸钠溶液,在常温下硒化反应12~20h,然后加入硫酸,沉淀离心、透析,再用无水乙醇沉淀离心,真空冷冻,用四氯化碳干燥后得硒化黄芪多糖。中国发明专利CN201210031988.9公开了党参多糖硒化的方法及其应用,该方法将亚硒酸加入到党参多糖的水溶液中,再加入氯化钡,然后在50~70℃下反应4~8小时,冷却,分离纯化得到硒化的党参多糖产物,硒含量为500-5000μg/g,具有显著的抗肿瘤和提高免疫力活性。中国发明专利CN201710418708.2公开了硒化莲藕多糖及其制备方法与应用,该方法采用莲藕多糖与亚硒酸钠进行反应,制备方法简单,产品硒含量高,能够有效抑制脂肪细胞分化,起到有效控脂、降脂作用。但是上述专利或专利申请中硒化技术存在试剂环境污染,反应时间长,产品得率低,副产物多等缺点。
发明内容
本发明所解决的技术问题在于提供一种具有显著的细胞抗氧化酶活性和α-葡萄糖甘酶的抑制活性的海蒿子多糖硒及其制备方法,所得海蒿子多糖硒具有抗氧化和降血糖作用。
本发明另一目的在于提供海蒿子多糖硒在制备具有抗氧化与降血糖功效的膳食补充剂中的应用。
硒是哺乳动物的必需微量元素,是谷胱甘肽过氧化物酶的主要活性成分,具有清除自由基、保护细胞、拮抗毒素、提高人体免疫功能等作用。还有保护骨髓造血功能及潜在的抗癌、抗衰老的多种作用即。目前己知的与缺硒有关的疾病有多种,包括心血管疾病、糖尿病、肝病、甲状腺功能失衡、癌症、免疫系统功能紊乱等。有些疾病特别是危害老年人内分泌代谢性疾病,如糖尿病、前列腺增生症、脑萎缩等均与缺硒有关。机体缺硒时,淋巴细胞的特异性和细胞毒作用会明显降低。而吞噬细胞的活性及抗体的生成也减少。自由基和脂质过氧化物参与了病毒性肝炎的病理过程,使肝脏超微结构发生病理性改变,硒能清除自由基及其脂质过氧化物,加速肝功能改善,达到保肝抗炎的目的。硒与金属有很强的亲和力,它在人体内同金属结合能形成金属-硒-蛋白质复合物,通过这种方式将对人体有毒害的铅、汞、砷、银等元素排出体外。因此,人们把硒元素誉为“天然解毒剂”。但同时,硒又是极毒元素,营养剂量范围小,使用时剂量难以控制。摄入过量的硒可导致体内累积,引发毒性和致畸变性。
硒在自然界中的存在形式分为无机硒和有机硒两种,常见的无机硒有亚硒酸钠和硒酸钠,有机硒包括:硒多糖、硒蛋白、硒核酸等。与无机硒相比,有机硒具有吸收率和生物活性高、毒性低、环境污染小等特点,是目前硒化学研究的一个热点;硒多糖的生物活性普遍高于多糖和硒,更易于为机体吸收和利用。
海蒿子多糖作为海蒿子中的主要功能成分之一,来源广泛,由多种单糖组成,具有较好水溶性和稳定性,可以用于液体、固态、粉末、片剂、冲剂,胶囊,口服液等保健品中,具有较好的市场应用价值。
本发明目的通过以下技术方案实现:
一种海蒿子多糖硒的制备方法,包括以下步骤:
1)原料预处理:将海蒿子原料,干燥,粉碎;以g和mL分别为质量和体积单位,将海蒿子干粉和乙醇按照固液质量体积比1:3~1:6混合,于60~80℃加热回流2~6h,离心分离残留物,重复加热回流和过滤,残留物干燥;
2)多糖提取:以g和mL分别为质量和体积单位,将经预处理的干粉按料液质量体积比为1:10~1:50与水混合,于温度为65~95℃下浸提,浸提时间为1.0~5h,浸提次数为2~5次;离心分离得到海蒿子多糖提取液,减压浓缩到原体积的1/4~1/10,得到海蒿子多糖的浓缩液;
3)脱蛋白:采用Sevag法对海蒿子多糖浓缩液进行脱蛋白处理,多糖浓缩液与Sevag试剂的体积比为3:1~6:1,振荡20~40min,离心后保留上层糖液,重复脱蛋白处理10~20次,并去除残留的Sevag试剂;
4)脱色:将脱蛋白后的海蒿子多糖,加入大孔树脂,进行静态脱色处理;浓缩液与大孔树脂的体积比为1:1~5:1,温度为30~45℃,时间为8~12h,用滤纸过滤后得到脱色后的多糖滤液;
5)醇沉:将步骤4)中浓缩液加入无水乙醇,调节乙醇的最终体积浓度为60~85%,在0~5℃中静置12~24h,离心得到沉淀,收集沉淀,冷冻干燥后得到海蒿子多糖样品;
6)硒化反应:以g和mL分别为质量和体积单位,将海蒿子多糖按料液质量体积比10:1~50:1与稀硝酸混合,室温下搅拌30~60min,使其充分溶解,然后分别加入亚硒酸钠和氯化钡,加热至60~80℃,搅拌混匀,于100~500W微波功率下,反应3~5min,间歇重复反应10~25次,得海蒿子多糖硒溶液,冷却到室温后,用氢氧化钠溶液调节pH至7~10,再加入硫酸钠除去钡离子,离心得上清液,置于透析袋进行透析,收集透析袋内的溶液,冷冻干燥得海蒿子多糖硒。
为进一步实现本发明目的,优选地,海蒿子原料干燥为鼓风干燥,干燥温度低于65℃;所述重复加热回流和过滤的次数为2~4次;所述残留物干燥的温度为45~65℃,时间为24~48h。
优选地,步骤1),步骤2)和步骤5)的离心分离的离心力4000~8000g,离心时间10~20min;所述步骤6)中离心力为4000~10000g,离心时间2~5min。
优选地,Sevag试剂的氯仿和正丁醇体积比为3:1~6:1;所述的大孔树脂为AB-8、大孔树脂D101。
优选地,步骤6)中,所述的亚硒酸钠和氯化钡与海蒿子多糖质量比分别为1:1~3:1和1:1~4:1;所述稀硝酸的为体积分数为0.3%~0.8%的硝酸溶液;所述氢氧化钠溶液的质量分数为0.1%~1.0%;所述硫酸钠的添加量是氯化钡质量的2~3倍。
优选地,步骤6)中,所述浓缩透析是用截留分子量为1000~5000Da的透析袋透析,透析时间为24~48h,透析的温度为0~5℃。
一种海蒿子多糖硒,由上述方法制备;所述海蒿子多糖硒具有显著的α-葡萄糖甘酶抑制活性,优于阿卡波糖,并能提高细胞抗氧化能力,减轻氧化应激。
所述的海蒿子多糖硒在具有抗氧化与降血糖功效的健康食品和药物中的应用。
与现有技术相比,本发明具有如下效果和优点:
(1)本发明首次制备了海蒿子多糖硒,具有较理想的α-葡萄糖甘酶抑制活性,并且具有显著的细胞抗氧化酶活性,其α-葡萄糖甘酶抑制率提高40%-75%,已经明显优于降血糖药物阿卡波糖,可开发一种降血糖剂,用于预防和治疗2型糖尿病。
(2)本发明采用间歇式微波加热技术制备海蒿子多糖硒,反应时间短,硒化程度高,硒含量为2500-5000mg/kg,制备方法简单,所采用硒化试剂绿色环保,对环境无污染,可应用于产业化生产中。
(3)本发明通过对海蒿子多糖提取以及纯化步骤进行选择和调整,使得制备的海蒿子多糖纯度高,不含蛋白质和核酸等杂质。
附图说明
图1为实施例1海蒿子多糖的单糖组成离子色谱图。
图2为实施例1海蒿子多糖的红外光谱图。
图3为实施例1海蒿子多糖硒的红外光谱图。
图4为实施例1海蒿子多糖和海蒿子多糖硒对细胞内SOD活性的影响。
图5为实施例1海蒿子多糖和海蒿子多糖硒对细胞内GSH活性的影响。
图6为实施例1海蒿子多糖和海蒿子多糖硒对细胞内MDA含量的影响。
图7为实施例1海蒿子多糖硒对α-葡萄糖苷酶抑制作用。
具体实施方式
为更好地理解本发明,下面结合实施例对本发明做进一步的说明,但本发明的实施方式不限于此。
实施例1
1)将干燥的海蒿子粉,以g和mL分别为质量和体积单位,按海蒿子粉与95%乙醇的质量体积比为1:3,加入95%乙醇,于温度60℃下,加热回流为2h,于4000g离心力下,离心20min,分离得残留物,残留物重复上述操作2次,在45℃下干燥24h;
2)以g和mL分别为质量和体积单位,将经预处理的干粉按料液质量体积比为1:20与水混合,于温度为65℃下浸提,浸提时间为2h,浸提次数为2次;离心分离,合并提取液,50℃下减压浓缩到原体积的1/4,得到海蒿子多糖的浓缩液;
3)向浓缩液中加入Sevag试剂,浓缩液与Sevag试剂(氯仿与正丁醇体积比为3:1)的体积比为3:1,振荡20min,离心除去变性的蛋白质,重复脱蛋白10次,收集上层糖液,蒸发去除残留Sevag试剂;
4)将脱蛋白后的海蒿子多糖,加入大孔树脂,进行静态脱色处理;浓缩液与大孔树脂的体积比为1:1,温度为30℃,时间为12h,用滤纸过滤后得到脱色后的多糖滤液;
5)将步骤4)所得浓缩液加入无水乙醇,调节乙醇的最终体积浓度为75%,在0~5℃中静置12h,离心得到多糖沉淀,收集沉淀,冷冻干燥后得到海蒿子多糖样品;
6)以g和mL分别为质量和体积单位,按料液质量体积比10:1,将海蒿子多糖与0.6%稀硝酸进行混合,室温下搅拌6h,使其充分溶解,然后加入亚硒酸钠和氯化钡,亚硒酸钠和氯化钡的添加量,分别是海蒿子多糖用量的2倍和4倍,加热至65℃,于100W微波功率下反应5min,间歇式重复反应10次,得海蒿子多糖硒混合液,冷却到室温后,用0.1%氢氧化钠溶液调节pH至7,加入2倍氯化钡质量的硫酸钠除去钡离子,离心得上清液,置于3000Da透析袋进行透析36h,收集透析袋内的溶液,冷冻干燥制得海蒿子多糖硒。
实施例2
1)将干燥的海蒿子粉,以g和mL分别为质量和体积单位,按海蒿子粉与95%乙醇的质量体积比为1:5,加入95%乙醇,于温度70℃下,加热回流为4h,于4000g离心力下,离心20min,分离得残留物,残留物重复上述操作2次,在45℃下干燥24h;
2)以g和mL分别为质量和体积单位,将经预处理的干粉按料液质量体积比为1:50与水混合,于温度为85℃下浸提,浸提时间为1h,浸提次数为3次;离心分离,合并提取液,50℃下减压浓缩到原体积的1/10,得到海蒿子多糖的浓缩液;
3)向浓缩液中加入Sevag试剂,浓缩液与Sevag试剂(氯仿:正丁醇=3:1)的体积比为4:1,振荡30min,离心除去变性的蛋白质,重复脱蛋白10次,收集上层糖液,蒸发去除残留Sevag试剂;
4)将脱蛋白后的海蒿子多糖,加入大孔树脂,进行静态脱色处理;浓缩液与大孔树脂的体积比为5:1,温度为45℃,时间为8h,用滤纸过滤后得到脱色后的多糖滤液;
5)将步骤4)中浓缩液加入无水乙醇,调节乙醇的最终体积浓度为60%,在0~5℃中静置12h,离心得到多糖沉淀,冷冻干燥后得到海蒿子多糖样品;
6)按料液质量体积比20:1,将海蒿子多糖与0.3%稀硝酸进行混合,室温下搅拌6h,使其充分溶解,然后加入亚硒酸钠和氯化钡,亚硒酸钠和氯化钡的添加量,分别是海蒿子多糖用量的3倍和2倍,加热至50℃,于500W微波功率下反应3min,间歇式重复反应20次,得海蒿子多糖硒混合液,冷却到室温后,用1.0%的氢氧化钠溶液调节pH至8,加入2倍氯化钡质量的硫酸钠除去钡离子,离心得上清液,置于5000Da透析袋进行透析24h,收集透析袋内的溶液,冷冻干燥得海蒿子多糖硒。
实施例3
1)将干燥的海蒿子粉,以g和mL分别为质量和体积单位,按海蒿子粉与95%乙醇的质量体积比为1:5,加入95%乙醇,于温度70℃下,加热回流为4h,于4000g离心力下,离心20min,分离得残留物,残留物重复上述操作2次,在45℃下干燥24h;
2)以g和mL分别为质量和体积单位,将经预处理的干粉按料液质量体积比为1:40与水混合,于温度为75℃下浸提,浸提时间为1h,浸提次数为2次;离心分离,合并提取液,50℃下减压浓缩到原体积的1/8,得到海蒿子多糖的浓缩液;
3)向浓缩液中加入Sevag试剂,浓缩液与Sevag试剂(氯仿:正丁醇=3:1)的体积比为5:1,振荡20min,离心除去变性的蛋白质,重复脱蛋白15次,收集上层糖液,蒸发去除残留Sevag试剂;
4)将脱蛋白后的海蒿子多糖,加入大孔树脂,进行静态脱色处理;浓缩液与大孔树脂的体积比为4:1,温度为37℃,时间为10h,用滤纸过滤后得到脱色后的多糖滤液;
5)将步骤4)中浓缩液加入无水乙醇,调节乙醇的最终体积浓度为80%,在0~5℃中静置12h,离心得到多糖沉淀,冷冻干燥后得到海蒿子多糖样品;
6)按料液质量体积比15:1,将海蒿子多糖与0.8%稀硝酸进行混合,室温下搅拌6h,使其充分溶解,然后加入亚硒酸钠和氯化钡,亚硒酸钠和氯化钡的添加量,分别是海蒿子多糖用量的2倍和3倍,加热至60℃,于300W微波功率下反应4min,间歇式重复反应15次,得海蒿子多糖硒混合液,冷却到室温后,用0.5%的氢氧化钠溶液调节pH至7,加入1.5倍氯化钡质量的硫酸钠除去钡离子,离心得上清液,置于1000Da透析袋进行透析48h,收集透析袋内的溶液,冷冻干燥得海蒿子多糖硒。
按以上实施例1制得的海蒿子多糖硒通过以下方法进行结构鉴定和活性分析,实施例2和3的结果与实施例1相似。
实施例4:多糖的单糖组成分析
实验方法:称取5mg实施例1中制备的海蒿子多糖硒于安培瓶中,加入4mL的三氟乙酸(2M),酒精喷灯封口密封,置于105℃下水解6h,50℃条件下减压蒸干,并加入4mL的甲醇重复操作3次,保证完全去除过量的三氟乙酸,然后将残留物超声溶解,用5mL容量瓶定容,过0.22μm尼龙滤膜进行色谱分析。离子色谱检测条件为:采用离子色谱仪(ICS3000,美国戴安公司)进行检测,使用CarboPac PA20分析柱(3×150mm),检测器为安培电化学检测器;柱温:30℃;流速:0.5mL/min;进样量:20μL流动相:10%20mM NaOH和90%超纯水(0-16min),10%20mM NaOH,20%500mM CH3COONa和70%超纯水。根据标准品的保留时间,可以确定多糖样品中的单糖组成,并根据各单糖的峰面积及单糖的摩尔质量计算出样品单糖的摩尔百分比。
图1为海蒿子多糖的离子交换色谱可知,该海蒿子多糖主要由岩藻糖、半乳糖、葡萄糖、甘露糖、木糖、阿拉伯糖、葡萄糖糖醛酸和半乳糖醛酸组成,摩尔百分比含量分别为30.14%、18.00%、26.90%、9.24%、4.84%、1.10%、7.66%和2.16%,表明该多糖是一种酸性杂多糖。
实施例5:海蒿子多糖硒中硒含量测定
实验方法:精确称取0.1g(精确至0.001g)实施例1中制备的海蒿子多糖硒,在10mL的烧瓶中溶解,之后取其中1mL。置于150mL消化杯中,加入12mL混合酸溶液,浓硝酸与高氯酸的体积比为5:1,盖上表面皿冷消化过夜。次日于电热板上140-150℃加热消解,当溶液变为清亮无色并伴有浓白烟产生时,再继续加热至烧杯内剩余体积为1-2mL左右,切不可蒸干。冷却后,加入10mL超纯水继续加热赶酸至剩余体积为1-2mL,此步骤重复两次赶酸彻底。后转移至50mL容量瓶中,超纯水定容,备用。采用AFS-9130系列原子荧光光度计(AFS)进行测定。
采用硒标准溶液绘制标准曲线,测得实施例1中海蒿子多糖硒的硒含量为2500mg/kg,而海蒿子多糖中未检测到硒。
实施例6:红外光谱分析
实验方法:称取2mg实施例1中制备的海蒿子多糖硒与200mg干燥的KBr粉末混合均匀,在玛瑙研钵中研磨均匀后取少量混合物压片,制成约1mm厚的透明薄片。把压成的薄片放入傅里叶红外变换光谱仪(Vector 33,德国Bruker公司)中,在400-4000cm-1区间进行扫描,采集样品的红外吸收光谱图。其结果如附图2和附图3。
图2是海蒿子多糖的红外光谱图,图3是本实施例制备的样品的红外光谱图。通过对比,实施例1中制备的海蒿子多糖与海蒿子多糖硒的红外谱图很相似,表明它们具有相同的基本骨架。海蒿子多糖在3313cm-1和2930cm-1处吸收峰为O-H和C-H的伸缩振动吸收峰,1036cm-1处特征吸收峰为C-O伸缩振动吸收峰,1605cm-1处吸收峰峰是δ(OH)弯曲振动吸收峰。但是,与海蒿子多糖相比,多糖硒在675cm-1附近出现了一个明显的新的吸收峰,此峰对应的是Se-O-C的特征吸收峰,与此同时某些吸收峰有所减弱,在3479cm-1处吸收宽峰减弱变窄,说明O-H键减少,同时该吸收峰向高波段移动,说明O-H基团与硒发生了配位反应,而在1036cm-1处C-O伸缩振动吸收峰也显著减弱,表明海蒿子多糖与硒成功地发生了螯合反应。
实施例7:细胞抗氧化酶活性
实验方法:选用人肝癌细胞HepG2进行细胞抗氧化活性测定。首先将复苏的HepG2细胞于37℃、5%CO2培养箱中进行培养,每2-3天更换1次培养液,到细胞数长到培养瓶80%左右时进行传代。选用12-40代的处于对数生长期的HepG2细胞,调整细胞浓度为5×105个/mL,接种于6孔细胞培养板中,分别向每孔中添加2mL的细胞悬浮液,将6孔板置于37℃、5%CO2培养箱中进行培养,24h后吸去培养基,并用2mL的无菌PBS洗涤1次,样品组加入不同浓度的样品溶液,正常组(Normal组)和模型组(Model组)加入相同体积的细胞培养基,继续放在培养箱中孵育2h,再次吸去每个孔中的培养基,并用PBS洗涤6次,然后分别向每孔中加入2mL ABAP溶液(600μM),正常组每孔中加入2mL PBS。于培养箱中孵育1.5h后,弃掉ABAP溶液,并用预冷的PBS冲洗2次,每孔加入150μL的细胞裂解液,冰浴10min,采用细胞刮刀收集细胞悬浮液,于14000g离心力下,离心10min,收集上清液,分装后储存于-80℃冰箱备用。采用BCA法测定细胞裂解液中的蛋白含量,并根据ELISA试剂盒测定步骤测定细胞裂解液的抗氧化酶活性:超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px);和丙二醛(MDA)的含量。
通过测定胞内SOD、GSH-Px的活性和MDA含量来评价海蒿子多糖和海蒿子多糖硒的细胞抗氧化能力,结果如附图4,5,6所示。氧化损伤模型组中抗氧化酶活性显著低于空白对照组,其中SOD和GSH-Px的活性分别下降了66.65%和63.41%,而MDA含量提高了87.5%,这表明ABAP诱导氧化损伤HepG2细胞模型造模成功。海蒿子多糖和海蒿子多糖硒能够提高氧化损伤HepG2细胞的胞内SOD和GSH-Px活性,而MDA含量下降,表明二者均能够提高细胞抗氧化能力,但海蒿子多糖硒的抗氧化酶活性比原海蒿子多糖提高了10%-25%。这可能由于硒是机体抗氧化酶的重要组成元素,海蒿子多糖硒以有机硒的形式,被细胞吸收利用,从而参与合成细胞抗氧化酶,提高抗氧化能力。
实施例8:α-葡萄糖甘酶的抑制活性
实验方法:将100μLα-葡萄糖甘酶溶液(0.35U/mL)与50μL样品溶液(0.3125-5mg/mL)混合,涡旋均匀,于37℃条件下孵育10min,然后向混合溶液中加入100μL pPNG溶液(1.5mM)启动反应,混匀后,在37℃条件下孵育20min,最后加入1mL Na2CO3溶液(1M)终止反应,测定405nm波长处吸光度值。α-葡萄糖苷酶的抑制率计算公式如下:
抑制率(%)=[1—(Asample—Acontrol-1)/Acontrol-2]×100
其中,Asample是多糖,酶和pPNG混合液的吸光度值;Acontrol-1是缓冲溶液代替酶溶液后混合物的吸光度;Acontrol-2是缓冲溶液代替样品溶液的吸光度值。阿卡波糖用作阳性对照。
海蒿子多糖和海蒿子多糖硒对α-葡萄糖苷酶的抑制活性,结果如附图7所示。可以看出,海蒿子多糖和海蒿子多糖硒对α-葡萄糖苷酶具有显著的抑制作用,并且呈剂量依赖型。在多糖低浓度0.3125mg/mL时,阿卡波糖对α-葡萄糖苷酶的抑制率都大于海蒿子多糖和海蒿子多糖硒,而当浓度为0.625mg/mL时,抑制率顺序为:海蒿子多糖硒>阿卡波糖。此外,相比海蒿子多糖,海蒿子多糖硒对α-葡萄糖苷酶抑制率提高了40%-75%。
α-淀粉酶和α-葡萄糖甘酶是人体内碳水化合物的两种关键消化酶,α-淀粉酶特异催化水解α-(1,4)-糖苷键,生成寡糖;再通过α-葡萄糖苷酶使寡糖水解生成葡萄糖,进入血液使血糖升高。因此,抑制α-淀粉酶和α-葡萄糖甘酶活性,能够有效降低碳水化合物的消化速度,降低餐后血糖水平,提高胰岛素的敏感性,用于预防和治疗2型糖尿病。本发明的海蒿子多糖硒是一种理想的α-葡萄糖苷酶抑制剂,其α-葡萄糖苷酶抑制活性强于常见降血糖药物阿卡波糖,由于阿卡波糖不仅价格高昂,而且长期服用会带来胰岛素抵抗和毒副作用,因此,海蒿子多糖硒可开发一种天然安全的降血糖剂,用于预防和治疗2型糖尿病。
实施例9:海蒿子多糖硒口服液的制备
制备过程:将实施例1中制备的海蒿子多糖硒溶于无菌超纯水,配制成5mg/mL的样品溶液,以样品溶液质量计,加入5.0%的蔗糖,3.0%的蜂蜜,0.2%的柠檬酸,0.15%的苯甲酸钠混合均匀后,至溶液澄清无沉淀,罐装于棕色玻璃瓶中,每支10mL,经紫外灭菌处理,即制得海蒿子多糖硒口服液,每日1支,餐后半小时服用。
实施例10:海蒿子多糖硒含片的制备
制备过程:将实施例1中的海蒿子多糖硒、乳糖、甘露糖醇、可溶性淀粉分别经粉碎机粉碎,过80目筛,将海蒿子多糖硒20%、甘露糖醇50%、乳糖15%和淀粉15%混合均匀后,慢慢加入适量蒸馏水,同时不断搅拌,制成软硬适中的软材。以20目筛为造粒工具,把软材紧握成团,压过筛子,使软材变为颗粒状。将湿粒置于60℃干燥箱中干燥3h左右,每隔0.5h翻动1次,以加快干燥速度。颗粒干燥后,再过1次16目筛。然后将1%硬脂酸镁和1%柠檬酸加入整粒混匀后,加盖静置一段时间,用三角形冲模压片机,压片成形;片剂放在紫外线下照射15~20min,然后及时包装。每片质量为1g,一次1片,每日1次。
本发明的实施方式并不受所述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (10)
1.一种海蒿子多糖硒的制备方法,其特征在于包括以下步骤:
1)原料预处理:将海蒿子原料,干燥,粉碎;以g和mL分别为质量和体积单位,将海蒿子干粉和乙醇按照固液质量体积比1:3~1:6混合,于60~80℃下,加热回流2~6h,离心分离残留物,残留物干燥;
2)多糖提取:以g和mL分别为质量和体积单位,将经预处理的干粉按料液质量体积比为1:10~1:50与水混合,于温度为65~95℃下浸提,浸提时间为1.0~5h,浸提次数为2~5次;离心分离得到海蒿子多糖提取液,减压浓缩到原体积的1/4~1/10,得到海蒿子多糖的浓缩液;
3)脱蛋白:采用Sevag法对海蒿子多糖浓缩液进行脱蛋白处理,离心后保留上层糖液,重复脱蛋白处理10~20次,并旋转蒸发去除残留的Sevag试剂;
4)脱色:将脱蛋白后的海蒿子多糖,加入大孔树脂,进行静态脱色处理;浓缩液与大孔树脂的体积比为1:1~5:1,温度为30~45℃,时间为8~12h,用滤纸过滤后得到脱色后的多糖滤液;
5)醇沉:将步骤4)中浓缩液加入无水乙醇,调节乙醇的最终体积浓度为60~85%,在0~5℃中静置12~24h,离心得到沉淀,收集沉淀,冷冻干燥后得到海蒿子多糖;
6)硒化反应:以g和mL分别为质量和体积单位,将海蒿子多糖按料液质量体积比10:1~50:1与稀硝酸混合,室温下搅拌30~60min,使其充分溶解,然后分别加入亚硒酸钠和氯化钡,加热至60~80℃,搅拌混匀,于100~500W微波功率下,反应3~5min,间歇重复反应10~20次,得海蒿子多糖硒溶液,冷却到室温后,用氢氧化钠溶液调节pH至7~10,再加入硫酸钠除去钡离子,离心得上清液,置于透析袋进行透析,收集透析袋内的溶液,冷冻干燥得海蒿子多糖硒。
2.根据权利要求1所述的海蒿子多糖的制备方法,其特征在于,步骤1)海蒿子原料干燥为鼓风干燥,干燥温度低于65℃;所述加热回流为重复加热回流,次数为2~4次;所述残留物干燥的温度为45~65℃,时间为24~48h。
3.根据权利要求1所述的海蒿子多糖硒的制备方法,其特征在于,所述步骤1),步骤2)和步骤5)的离心分离的离心力4000~8000g,离心时间10~20min;所述步骤6)中离心力为4000~10000g,离心时间2~5min。
4.根据权利要求1所述的海蒿子多糖硒的制备方法,其特征在于,步骤3)所述的Sevag试剂的氯仿和正丁醇体积比为3:1~6:1;所述的脱蛋白处理,每次振荡时间为10~30min。
5.根据权利要求1所述的海蒿子多糖硒的制备方法,其特征在于,步骤6)中,所述的亚硒酸钠和氯化钡的添加量与海蒿子多糖质量比分别为1:1~3:1和1:1~4:1;所述稀硝酸的为体积分数为0.3%~0.8%的硝酸溶液;所述的氢氧化钠溶液的质量分数为0.1%~1.0%;所述硫酸钠的添加量是氯化钡质量的2~3倍。
6.根据权利要求1所述的海蒿子多糖硒的制备方法,其特征在于,步骤6)中,所述浓缩透析是用截留分子量为1000~5000Da的透析袋透析,透析时间为24~48h,透析的温度为0~5℃。
7.根据权利要求1所述的海蒿子多糖硒的制备方法,其特征在于,步骤4)中,所述的大孔树脂为AB-8、大孔树脂D101。
8.根据权利要求1所述的海蒿子多糖硒的制备方法,其特征在于,步骤5)中,所述的海蒿子多糖是一种酸性杂多糖,主要由岩藻糖、半乳糖、葡萄糖、木糖和葡萄糖糖醛酸组成,岩藻糖、半乳糖、葡萄糖、木糖和葡萄糖糖醛酸的摩尔百分比含量分别为20~30%、15~25%、20~30%、5~15%和5~10%。
9.一种海蒿子多糖硒,其特征在于,其由权利要求1-8任一项所述的制备方法制得。
10.权利要求9所述的海蒿子多糖硒在制备具有抗氧化与降血糖功效的膳食补充剂中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910268836.2A CN110078840A (zh) | 2019-04-04 | 2019-04-04 | 一种海蒿子多糖硒及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910268836.2A CN110078840A (zh) | 2019-04-04 | 2019-04-04 | 一种海蒿子多糖硒及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110078840A true CN110078840A (zh) | 2019-08-02 |
Family
ID=67414237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910268836.2A Pending CN110078840A (zh) | 2019-04-04 | 2019-04-04 | 一种海蒿子多糖硒及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110078840A (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110396138A (zh) * | 2019-08-29 | 2019-11-01 | 华南理工大学 | 一种褐藻多糖脱色脱蛋白的方法 |
CN110679996A (zh) * | 2019-10-31 | 2020-01-14 | 湖北中烟工业有限责任公司 | 一种含富硒化多糖的烟叶 |
CN111165867A (zh) * | 2019-10-31 | 2020-05-19 | 湖北中烟工业有限责任公司 | 一种利用烟叶多糖及其衍生多糖定香的烟丝 |
CN111285939A (zh) * | 2020-03-19 | 2020-06-16 | 华南理工大学 | 一种具有抗氧化和调节肠道菌群功效的海蒿子多糖及其制备方法与应用 |
CN111978420A (zh) * | 2020-08-19 | 2020-11-24 | 青岛谦和信科技服务有限公司 | 一种螺旋藻硒多糖的制备方法 |
CN112710822A (zh) * | 2020-12-17 | 2021-04-27 | 四川农业大学 | 一种食用菌多糖及其硒化衍生物的体外模拟消化方法 |
CN114409818A (zh) * | 2022-01-24 | 2022-04-29 | 沈阳化工大学 | 一种毛酸浆多糖硒化物制备方法及应用 |
CN115975062A (zh) * | 2022-12-23 | 2023-04-18 | 中山火炬职业技术学院 | 一种具有抗氧化和/或抗皱功效的富硒石斛多糖及其制备方法 |
CN116535533A (zh) * | 2023-04-28 | 2023-08-04 | 宁波御菌生物技术有限公司 | 一种含硒桑黄多糖的提取工艺 |
-
2019
- 2019-04-04 CN CN201910268836.2A patent/CN110078840A/zh active Pending
Non-Patent Citations (2)
Title |
---|
HENG XIAO ET AL.: ""Physicochemical characterization, antioxidant and hypoglycemic activities of selenized polysaccharides from Sargassum pallidum"", 《INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES》 * |
王国全等: ""微波辅助合成款冬花硒多糖的研究"", 《临床医学研究与实践》 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110396138B (zh) * | 2019-08-29 | 2021-02-19 | 华南理工大学 | 一种褐藻多糖脱色脱蛋白的方法 |
US11572419B2 (en) | 2019-08-29 | 2023-02-07 | South China University Of Technology | Method for decolorizing and deproteinizing brown algae polysaccharides |
CN110396138A (zh) * | 2019-08-29 | 2019-11-01 | 华南理工大学 | 一种褐藻多糖脱色脱蛋白的方法 |
WO2021036864A1 (zh) * | 2019-08-29 | 2021-03-04 | 华南理工大学 | 一种褐藻多糖脱色脱蛋白的方法 |
CN110679996B (zh) * | 2019-10-31 | 2022-02-08 | 湖北中烟工业有限责任公司 | 一种含富硒化多糖的烟叶 |
CN111165867A (zh) * | 2019-10-31 | 2020-05-19 | 湖北中烟工业有限责任公司 | 一种利用烟叶多糖及其衍生多糖定香的烟丝 |
CN110679996A (zh) * | 2019-10-31 | 2020-01-14 | 湖北中烟工业有限责任公司 | 一种含富硒化多糖的烟叶 |
CN111285939A (zh) * | 2020-03-19 | 2020-06-16 | 华南理工大学 | 一种具有抗氧化和调节肠道菌群功效的海蒿子多糖及其制备方法与应用 |
CN111285939B (zh) * | 2020-03-19 | 2022-04-22 | 华南理工大学 | 一种具有抗氧化和调节肠道菌群功效的海蒿子多糖及其制备方法与应用 |
CN111978420A (zh) * | 2020-08-19 | 2020-11-24 | 青岛谦和信科技服务有限公司 | 一种螺旋藻硒多糖的制备方法 |
CN112710822A (zh) * | 2020-12-17 | 2021-04-27 | 四川农业大学 | 一种食用菌多糖及其硒化衍生物的体外模拟消化方法 |
CN114409818A (zh) * | 2022-01-24 | 2022-04-29 | 沈阳化工大学 | 一种毛酸浆多糖硒化物制备方法及应用 |
CN114409818B (zh) * | 2022-01-24 | 2022-11-11 | 沈阳化工大学 | 一种毛酸浆多糖硒化物制备方法及应用 |
CN115975062A (zh) * | 2022-12-23 | 2023-04-18 | 中山火炬职业技术学院 | 一种具有抗氧化和/或抗皱功效的富硒石斛多糖及其制备方法 |
CN116535533A (zh) * | 2023-04-28 | 2023-08-04 | 宁波御菌生物技术有限公司 | 一种含硒桑黄多糖的提取工艺 |
CN116535533B (zh) * | 2023-04-28 | 2024-06-07 | 宁波御菌生物技术有限公司 | 一种含硒桑黄多糖的提取工艺 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110078840A (zh) | 一种海蒿子多糖硒及其制备方法与应用 | |
CN109303922B (zh) | 一种刺梨多糖功能化纳米硒复合物及其制备方法与在降糖药物中的应用 | |
CN109400734A (zh) | 一种刺梨多糖及其制备方法与应用 | |
CN101036698B (zh) | 一种桑叶提取物及其制备方法与应用 | |
US10835552B2 (en) | Method for preparing linseed polysaccharide having antiviral activity and immunological activity, and use of the linseed polysaccharide | |
CN112961260A (zh) | 一种具有显著抗炎活性龙须菜多糖及其制备方法与应用 | |
CN114874344B (zh) | 青稞嫩叶碱提多糖的制备方法及其应用 | |
CN109608557A (zh) | 枸杞多糖提取分离和纯化方法、枸杞糖肽及制备方法 | |
CN113024685A (zh) | 一种低分子量竹荪菌托多糖及其制备方法与应用 | |
CN107456581A (zh) | 一种富硒大米植物硒蛋白胶囊材料及其制备方法 | |
CN110606900B (zh) | 一种具有抗氧化作用的木枣多糖的分离纯化方法 | |
CN106726889A (zh) | 金花茶有效成分的提取方法及制备保健品的用途 | |
CN104262500B (zh) | 一种具有免疫活性的新型红托竹荪多糖及其制备方法和应用 | |
CN110521903A (zh) | 一种具有抗霾清肺功效的罗汉果蜜及其生产方法 | |
CN103739731A (zh) | 树脂吸附法脱除香菇多糖农药残留和重金属残留方法 | |
CN113402626A (zh) | 一种香水莲花多糖提取物及其制备方法和应用 | |
KR20070089309A (ko) | 항균, 항산화 및 항암 활성을 갖는 우뭇가사리 농축소재의 제조방법 및 이를 함유하는 기능성식품조성물 | |
CN107296195A (zh) | 一种富氢饮料的制备方法 | |
CN108456258B (zh) | 一种铁皮石斛硒多糖制备方法 | |
CN112142868A (zh) | 一种羊肚菌多糖提取物、羊肚菌多糖含片及其制备方法 | |
CN112794925B (zh) | 一种阳春砂多糖及其制备方法和应用 | |
CN111096222B (zh) | 利用固定化球毛壳孢子提高人参不定根中人参皂苷含量的方法 | |
CN114249846A (zh) | 一种酸性莼菜多糖及其分离纯化方法和应用 | |
CN107793489A (zh) | 一种从灰树花中提取多糖奇果菌素的方法 | |
CN1164600C (zh) | 一种利用中药泽兰的块根制取双歧因子低聚糖的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190802 |
|
RJ01 | Rejection of invention patent application after publication |